Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 3Skin Diseases 2Neoplasms by Site 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Prostatic Neoplasms 1Precancerous Conditions 1Neoplasm Metastasis 1Kidney Neoplasms 1Hematologic Diseases 1Genital Neoplasms, Female 1Genital Diseases, Female 1Genital Diseases 1Female Urogenital Diseases and Pregnancy Complications 1Communicable Diseases 1Breast Neoplasms 1Breast Diseases 1Autoimmune Diseases 1

Interventions

exemestane 4entinostat 4Fulvestrant 4ribociclib 3palbociclib 3abemaciclib 3Anastrozole 3Trastuzumab 2Letrozole 2Gonadotropin-Releasing Hormone 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1taxane 1pertuzumab 1pembrolizumab 1ipatasertib 1figitumumab 1elacestrant 1dactolisib 1atezolizumab 1Watchful Waiting 1Trabectedin 1Tamoxifen 1STX-478 1RAD1901 1Paclitaxel 1Metformin 1Lapatinib 1Imlunestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Diseases × Watchful Waiting × Clear all
NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡